ONO-5920
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Involutional Osteoporosis
Conditions
Involutional Osteoporosis
Trial Timeline
Aug 1, 2002 → —
NCT ID
NCT00212667About ONO-5920
ONO-5920 is a phase 3 stage product being developed by Astellas Pharma for Involutional Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00212667. Target conditions include Involutional Osteoporosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00212667 | Phase 3 | Completed |
Competing Products
2 competing products in Involutional Osteoporosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Minodronic acid hydrate | Astellas Pharma | Phase 3 | 77 |
| ONO-5920 | Ono Pharmaceutical | Phase 3 | 77 |